On Friday, Lyra Therapeutics Inc (NASDAQ: LYRA) opened lower -5.82% from the last session, before settling in for the closing price of $0.27. Price fluctuations for LYRA have ranged from $0.21 to $6.79 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 58.51% over the past five years. Company’s average yearly earnings per share was noted -5.71% at the time writing. With a float of $56.00 million, this company’s outstanding shares have now reached $57.21 million.
Let’s look at the performance matrix of the company that is accounted for 88 employees. In terms of profitability, gross margin is -599.67%, operating margin of -4100.71%, and the pretax margin is -5567.64%.
Lyra Therapeutics Inc (LYRA) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Lyra Therapeutics Inc is 14.45%, while institutional ownership is 43.99%. The most recent insider transaction that took place on Nov 10 ’23, was worth 74,095. In this transaction Executive Chair of this company bought 25,000 shares at a rate of $2.96, taking the stock ownership to the 261,966 shares.
Lyra Therapeutics Inc (LYRA) Latest Financial update
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted -0.27 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.32) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.21 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -5.71% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.60% during the next five years compared to -21.63% drop over the previous five years of trading.
Lyra Therapeutics Inc (NASDAQ: LYRA) Trading Performance Indicators
Check out the current performance indicators for Lyra Therapeutics Inc (LYRA). In the past quarter, the stock posted a quick ratio of 3.60. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.63, a number that is poised to hit -0.21 in the next quarter and is forecasted to reach -0.74 in one year’s time.
Technical Analysis of Lyra Therapeutics Inc (LYRA)
Lyra Therapeutics Inc (NASDAQ: LYRA) saw its 5-day average volume 1.65 million, a positive change from its year-to-date volume of 1.64 million. As of the previous 9 days, the stock’s Stochastic %D was 51.69%. Additionally, its Average True Range was 0.02.
During the past 100 days, Lyra Therapeutics Inc’s (LYRA) raw stochastic average was set at 36.25%, which indicates a significant decrease from 47.09% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 77.81% in the past 14 days, which was higher than the 71.03% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.2653, while its 200-day Moving Average is $2.1455. Nevertheless, the first resistance level for the watch stands at $0.2781 in the near term. At $0.2974, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.3089. If the price goes on to break the first support level at $0.2473, it is likely to go to the next support level at $0.2358. The third support level lies at $0.2165 if the price breaches the second support level.
Lyra Therapeutics Inc (NASDAQ: LYRA) Key Stats
There are currently 65,457K shares outstanding in the company with a market cap of 15.96 million. Presently, the company’s annual sales total 1,560 K according to its annual income of -62,680 K. Last quarter, the company’s sales amounted to 600 K and its income totaled -48,130 K.
